Effect of statins on erythropoietin responsiveness in type 2-diabetic versus non-diabetic hemodialysis patients

Clinical Nephrology

Volumn 73, Issue 1, 2010, Pages 1-6

  Tangdhanakanond, K ^a   Raja, R ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Erythropoietin; Hemodialysis; Inflammation; Statins; Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; ALUMINUM; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; C REACTIVE PROTEIN; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRITIN; FOLIC ACID; HEMOGLOBIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; PARATHYROID HORMONE; PREALBUMIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; HEMATOCRIT; HEMODIALYSIS PATIENT; HUMAN; LABORATORY TEST; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT RESPONSE;

ADULT; AGED; ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; MALE; MEDICAL RECORDS; MIDDLE AGED; PATIENT SELECTION; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 74049160853     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp73001     Document Type: Article

References (18)

1. Eschbach JW. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989; 35: 134.
2. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis. 1989; 14: 14.
3. Mocks J, Franke W, Ehmer B, Scigalla P, Quarder O. Analysis of safety database for long-term epoetin-β treatment. A meta-analysis covering 3,697 patients. In: Pathogenetic and Therapeutic Aspects of Chronic Renal Failure. In: Koch KM, Stein G (eds). 12th Ed. New York: Marcel Dekker; 1997. p. 163-179.
4. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993; 328: 171.
5. Grutzmacher P, Ehmer B, Messinger D et al. Effect of aluminum overload on the bone marrow response to recombinant human erythropoietin. Contrib Nephrol. 1989; 76: 315.
6. 12 supplementation necessary in chronic hemodialysis patients with EPO treatment? Clin Nephrol. 1994; 42: 343.
7. Madour F, Bridges K, Brugnara NL et al. A population study of the interplay between iron, nutrition, and inflammation in erythropoiesis in hemodialysis patients. J Am Soc Nephrol. 1996; 7: 1456a.
8. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med. 1996; 334: 420-425.
9. Albitar S, Genin R, Fen-Chong M et al. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant. 1998; 13: 1206.
10. Goicoechea M, Martin J, de Sequera P et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int. 1998; 54: 1337-1343.
11. Barany P. Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant. 2001; 16: 224-227.
12. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997; 29: 565.
13. Albert MA, Danielson E, Rafai N, Ridker PM (The PRINCE investigators). Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. JAMA. 2001; 286: 64-70.
14. Diepeveen SH, Verhoeven GW, Van Der Palen J et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomized, controlled trial. J Int Med. 2005; 257: 438-445.
15. Strippoli GF, Navaneethan SD, Johnson DW et al. Effects of statins in patients with chronic kidney desease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008; 336: 645.
16. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999; 353: 983-984.
17. Sirken G, Kung SC, Raja R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J. 2003; 49: 422.
18. Biesenbach G, Schmekal B, Eichbauer-Sturm G, Janko O. Erythropoietin requirement in patients with Type 2 diabetes mellitus on maintenance hemodialysis therapy. Wien Klin Wochenschr. 2004; 116: 844-848.